TY - JOUR
T1 - Memory T cell, exhaustion, and tumor immunity
AU - Ando, Makoto
AU - Ito, Minako
AU - Srirat, Tanakorn
AU - Kondo, Taisuke
AU - Yoshimura, Akihiko
N1 - Funding Information:
This work was supported by JSPS KAKENHI (S) [JP17H06175], Challenging Research (P) [JP18H05376], and AMED-CREST [JP19gm1110009] grants for A.Y. This work was also supported by JSPS KAKENHI [17K15667, 19H04817, and 19K16618], AMED-PRIME [19gm6210012], JSPS KAKENHI [19H04817 and 19K16618], for M.I., as well as by the Tomizawa Jun-ichi & Keiko Fund of Molecular Biology Society of Japan for Young Scientists, a Research grant for young investigators by The Mitsubishi Foundation, the Mochida Memorial Foundation for Medical and Pharmaceutical Research, the Takeda Science Foundation, the Uehara Memorial Foundation, the Naito Memorial Foundation, the Kanae Foundation, the SENSHIN Medical Research Foundation, and Keio Gijuku Academic Developmental Funds.
Publisher Copyright:
© 2019, © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of the Japanese Society of Clinical Immunology.
PY - 2020/1/2
Y1 - 2020/1/2
N2 - CD8+T cells are important in protective immunity against intracellular pathogens and tumors. In chronic infections or cancer, CD8+T cells are constantly exposed to antigens and inflammatory signals. Such excessive and constitutive signals lead to the deterioration of T cell function, called ‘exhaustion’. Exhausted T cells are characterized by low proliferation in response to antigen stimulation, progressive loss of effector function (cytokine production and killing function), expression of multiple inhibitory receptors such as PD-1, Tim3, and LAG3, and metabolic alterations from oxidative phosphorylation to glycolysis. These dysfunctions are associated with altered transcriptional programs and epigenetic regulations and recent studies suggested that NR4a and TOX transcription factors are deeply involved in exhaustion phenotypes. However, an increase the early memory T cells including stem cell memory T (TSCM) cells is critical for T cell persistence and efficient tumor killing especially for adoptive cancer immunotherapy such as CAR-T cell therapy. An increasing amount of evidence supports the therapeutic potential of targeting exhausted T cells and TSCM cells. We have begun to understand the molecular mechanisms of T cell exhaustion and early memory formation, and the clinical application of converting exhausted T cells to rejuvenated early memory T cells is the goal of our study.
AB - CD8+T cells are important in protective immunity against intracellular pathogens and tumors. In chronic infections or cancer, CD8+T cells are constantly exposed to antigens and inflammatory signals. Such excessive and constitutive signals lead to the deterioration of T cell function, called ‘exhaustion’. Exhausted T cells are characterized by low proliferation in response to antigen stimulation, progressive loss of effector function (cytokine production and killing function), expression of multiple inhibitory receptors such as PD-1, Tim3, and LAG3, and metabolic alterations from oxidative phosphorylation to glycolysis. These dysfunctions are associated with altered transcriptional programs and epigenetic regulations and recent studies suggested that NR4a and TOX transcription factors are deeply involved in exhaustion phenotypes. However, an increase the early memory T cells including stem cell memory T (TSCM) cells is critical for T cell persistence and efficient tumor killing especially for adoptive cancer immunotherapy such as CAR-T cell therapy. An increasing amount of evidence supports the therapeutic potential of targeting exhausted T cells and TSCM cells. We have begun to understand the molecular mechanisms of T cell exhaustion and early memory formation, and the clinical application of converting exhausted T cells to rejuvenated early memory T cells is the goal of our study.
UR - http://www.scopus.com/inward/record.url?scp=85076442491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076442491&partnerID=8YFLogxK
U2 - 10.1080/25785826.2019.1698261
DO - 10.1080/25785826.2019.1698261
M3 - Review article
C2 - 31822213
AN - SCOPUS:85076442491
SN - 0911-4300
VL - 43
SP - 1
EP - 9
JO - Immunological Medicine
JF - Immunological Medicine
IS - 1
ER -